Davion Healthcare PLC F-1 registration statements
The S-1’s counterpart for foreign private issuers registering shares for sale in the United States.
Davion Healthcare Plc, a pre-revenue company specializing in non-invasive home health tests, filed an amended F-1 registration statement for a direct listing on the Nasdaq Global Market under the symbol DAVI, with commercial product launches expected in H1 2026.
Davion Healthcare Plc, a pre-revenue medical device company, filed an amended registration statement for a direct listing on the Nasdaq Global Market, highlighting its non-invasive home test portfolio and a significant licensing deal with NeuRX Health Inc.
Davion Healthcare Plc, a pre-revenue medical device company, is preparing for a direct listing on the Nasdaq Global Market, registering 25 million ordinary shares for resale by existing shareholders.
Davion Healthcare Plc, a pre-revenue Irish company specializing in non-invasive home diagnostic tests, is pursuing a direct listing on the NASDAQ Global Market under the ticker DAVI.